improving the half-life and efficacy of ADCs through strategies like the use of albumin-binding domains or small-format antibodies is an area of active research. Design principles for bispecific ...

LBL-034 is an investigational GPRC5D-targeted CD3 bispecific antibody. The Food and Drug Administration (FDA) has granted Orphan Drug designation to LBL-034 for the treatment of multiple myeloma.

The field of bispecific antibodies is experiencing a remarkable surge, presenting a substantial commercial opportunity in the biopharmaceutical landscape. With close to 14 bispecific antibodies ...

Building upon the foundation established by monoclonal antibodies, this evolving field includes various constructs such as bispecific, trispecific, and tetraspecific antibodies. Among these, ...

MSD has an extensive pipeline in oncology but hasn't been a player in bispecific antibodies. Now, it has bolted on a bispecific via a $1.3 billion licensing deal with Curon Biopharma. The big ...

The company had completed a phase 1 trial of CDX-585, a bispecific antibody targeting PD-1 and ILT4 in patients with advanced or metastatic solid tumors that had not been halted by standard-of ...

Ideaya Biosciences has decided to go ahead with its plans to grab a bispecific antibody-drug conjugate (ADC) from Biocytogen, exercising an option to pick up a preclinical asset from the Chinese ...

Video content above is prompted by the following: This presentation is to do a deep dive into the operationalization of bispecific antibody (BsAb) therapy in community practices. Please summarize the ...